Inside the GENOME

Myriad Oncology Live episodes are recordings of an open-forum webinar hosted by Dr. Thomas Slavin. The opinions and views expressed in this recording do not necessarily represent those of Myriad Genetics or its affiliates. To participate in a future recording, visit myriad-oncology.com/myriad-oncology-live for a list of dates, times, and subjects.


Many studies were referenced in this episode, please see links below:

Yanes T, et al. Clinical applications of Polygenic breast cancer risk: a critical review and perspective of an emerging field. Breast Cancer Res 22, 21 (2020). https://pubmed.ncbi.nlm.nih.gov/32066492/

 Mars et al study link: https://www.nature.com/articles/s41467-020-19966-5

Rosner et al study: https://cebp.aacrjournals.org/content/cebp/early/2020/12/04/1055-9965.EPI-20-0900.full.pdf

Lakeman et al study: https://www.nature.com/articles/s41436-020-0884-4

Barnes et al study: https://www.nature.com/articles/s41436-020-0862-x

 https://www.nature.com/articles/ng.3841

https://pubmed.ncbi.nlm.nih.gov/25862352/

This is the study where the chart comes from : https://pubmed.ncbi.nlm.nih.gov/32620971/

Here is the abstract from ASCO about ancestrally unbiased breast cancer (BC) risk assessment. Dr. Pederson also presented this material during the meeting. https://meetinglibrary.asco.org/record/197017/abstract

Here is the Tischkowitz paper Dr. Slavin was discussing: https://www.acmg.net/PDFLibrary/41436_2021_1151_OnlinePDF.pdf

Gallagher paper (chart was from this paper) https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2767768

 Yanes T, et al. Women's responses and understanding of polygenic breast cancer risk information. Fam Cancer. 2020 Oct;19(4):297-306. https://pubmed.ncbi.nlm.nih.gov/32430685/

https://cancerpreventionresearch.aacrjournals.org/content/early/2020/10/23/1940-6207.CAPR-20-0154?versioned=true

Hughes et al paper where data from chart is derived: https://ascopubs.org/doi/full/10.1200/PO.20.00246

Risk of Breast Cancer Among Carriers of Pathogenic Variants in Breast Cancer Predisposition Genes Varies by Polygenic Risk Score https://ascopubs.org/doi/full/10.1200/JCO.20.01992

Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer  https://www.nejm.org/doi/full/10.1056/NEJMoa2105215

Myriad Oncology Live episodes are recordings of an open-forum webinar hosted by Dr. Thomas Slavin. The opinions and views expressed in this recording do not necessarily represent those of Myriad Genetics or its affiliates. To participate in a future recording, visit myriad-oncology.com/myriad-oncology-live for a list of dates, times, and subjects.

Myriad Oncology Live episodes are recordings of an open-forum webinar hosted by Dr. Thomas Slavin. The opinions and views expressed in this recording do not necessarily represent those of Myriad Genetics or its affiliates. To participate in a future recording, visit myriad-oncology.com/myriad-oncology-live for a list of dates, times, and subjects.

Myriad Oncology Live episodes are recordings of an open-forum webinar hosted by Dr. Thomas Slavin. The opinions and views expressed in this recording do not necessarily represent those of Myriad Genetics or its affiliates. To participate in a future recording, visit myriad-oncology.com/myriad-oncology-live for a list of dates, times, and subjects.

Myriad Oncology Live episodes are recordings of an open-forum webinar hosted by Dr. Thomas Slavin. The opinions and views expressed in this recording do not necessarily represent those of Myriad Genetics or its affiliates. To participate in a future recording, visit myriad-oncology.com/myriad-oncology-live for a list of dates, times, and subjects.

Myriad Oncology Live episodes are recordings of an open-forum webinar hosted by Dr. Thomas Slavin. The opinions and views expressed in this recording do not necessarily represent those of Myriad Genetics or its affiliates. To participate in a future recording, visit myriad-oncology.com/myriad-oncology-live for a list of dates, times, and subjects.

Myriad Oncology Live episodes are recordings of an open-forum webinar hosted by Dr. Thomas Slavin. The opinions and views expressed in this recording do not necessarily represent those of Myriad Genetics or its affiliates. To participate in a future recording, visit myriad-oncology.com/myriad-oncology-live for a list of dates, times, and subjects.

 In this episode of Inside the Genome, Dr. Slavin is joined by three-time cancer survivor, Annie Parker. They discuss how early genetic testing had an impact on her journey through survivorship. 

About Our Guest: Annie Parker was one of the first women to be tested for BRCA mutations after experiencing cancer at an early age. She is an advocate for women’s health and runs the Annie Parker Foundation.

In this episode of Inside the GENOME, Dr. Slavin sits down with William J. Harb, MD, FACS, FASCRS. They discuss the importance of raising awareness for colorectal cancer.

About Our Guest:
Dr. William Harb is a board-certified colorectal surgeon, specializing in the treatment of diseases of the colon and rectum. Through his dedication and national recognition with hereditary colorectal cancer, genetic testing has become an integral part of his practice. Dr. Harb works at the Colorectal Center in Nashville, Tennessee.  https://thecolorectalcenter.com/ 

In this episode of Inside the GENOME, Dr. Slavin sits down with Nicole Lambert, President of Myriad Genetics. They discuss her background as a genetic counselor and how she came to her role as President of Myriad, her personal story with her own genetics and risk assessment which led to her decision to undergo preventative surgery, and how Myriad is at the forefront of breast cancer risk assessment.